BCM
GLUE icon

Bridgeway Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Bridgeway Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.7M Buy
528,698
+5,321
+1% +$102K 0.17% 175
2025
Q4 		$8.21M Buy
523,377
+164,527
+46% +$2.22M 0.17% 175
2025
Q3 		$2.66M Buy
358,850
+87,450
+32% +$463K 0.06% 455
2025
Q2 		$1.22M Buy
+271,400
New +$1.21M 0.03% 631
2024
Q4 		– Sell
-25,000
Closed -$133K – 1241
2024
Q3 		$133K Buy
+25,000
New +$126K ﹤0.01% 1123

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Bridgeway Capital Management's GLUE Position: Q1 2026 in Review

Bridgeway Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 1% in Q1 2026, buying an estimated $102K and bringing the position to 528,698 shares worth $8.7M. The position accounts for 0.17% of the portfolio, ranked #175.

Bridgeway Capital Management first reported a position in GLUE in Q3 2024 and has held it in 5 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Bridgeway Capital Management held 528,698 shares of Monte Rosa Therapeutics worth $8.7M as of Q1 2026.
  • Bridgeway Capital Management bought 5,321 Monte Rosa Therapeutics shares in Q1 2026, an estimated $102K.
  • Monte Rosa Therapeutics made up 0.17% of Bridgeway Capital Management's portfolio in Q1 2026, its #175 holding.
  • Bridgeway Capital Management first reported a position in Monte Rosa Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.